Novo Nordisk accepts U.S. Medicare price deal for obesity drugs (NVO:NYSE)

How will Tesla’s Optimus robot impact jobs? Why are US airlines canceling flights amid shutdown? What changes are Visa and Mastercard negotiating on fees? How is China’s inflation affecting global markets? Why did UPS and FedEx ground MD-11 planes? What caused the plunge in Asia’s AI stocks? How is the government shutdown harming the US economy?

Novo Nordisk accepts U.S. Medicare price deal for obesity drugs (NVO:NYSE)

seekingalpha.com/news/4515436-novo-nordisk-accepts-us-medicare-price-deal-for-obesity-drugs

said Wednesday it has agreed to the U.S. Inflation Reduction Act’s (IRA) negotiated maximum fair prices for semaglutide, the active ingredient in its popular drugs Ozempic and Wegovy, effective January 2027.
These drugs are part of the

This story appeared on seekingalpha.com, 2025-11-05 23:52:39.880000.